NanoBiCar NanoBiCar: A novel immunotherapy for infectious diseases
- Coordinator
- Universitat Politecnica De Valencia, Spain
- Runs
- 1 February 2025 to 31 January 2028
- Status
- Running
- EU funding
- €3.6m
- Total cost
- €3.6m
- Partners
- 12 organisations in 5 countries
- Type
- European Innovation Council
- Grant agreement
- 101186252
What the project is doing
In the project's own words, from its summary on CORDIS.
It is estimated that 20% of global mortality is associated with bacterial infections. The current treatment is based on the use of antibiotics, but nonspecific effects, difficulty in reaching intracellular bacteria, and the generation of antimicrobial resistance limit its effectiveness. Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent: Mycobacterium tuberculosis (Mtb). Multidrug-resistant TB (MDR-TB) is a major threat to global health security.
A quarter of the population is latently infected with Mtb, many of them MDR strains, so preventing new cases of this growing reservoir is a priority. Immunotherapy is an alternative option, but its effectiveness is based on the immune response capacity of a compromised host. NanoBiCar's long-term vision is to revolutionize the current treatment of bacterial infections with a groundbreaking and innovative immunotherapeutic approach, overcoming many of the problems associated with treatment, with potential application beyond this field.
Using TB as a proof of concept, three immunotherapeutic platforms, using mRNAs encapsulated in lipid nanoparticles, not tested in bacterial diseases will be used to eliminate intra (IC) and extracellular (EC) bacteria. These immunotherapeutic methods are safe, economical, accessible, ready-to-use, and specific, targeting latent/ acute/chronic infections, without generating resistance and suitable for use in high-burden, low-resource settings; effective regardless of the antibiotic resistance of the strain and its niche (IC or EC), the genetic background of the host and the degree of immunocompetence.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitat Politecnica De Valencia | Valencia | Spain | Coordinator |
| Acosta Dominguez Armando | Spain | Participant | |
| Consorcio Centro De Investigacion Biomedica En Red M.p. | Madrid | Spain | Third party |
| Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe | Valencia | Spain | Third party |
| Institut De Investigacio En Ciencies De La Salut Germans Trias I Pujol | Badalona Barcelona | Spain | Participant |
| Sarmiento Garcia San Miguel Maria Elena | Spain | Participant | |
| Victor Pallaruelo-Santamaria | Spain | Participant | |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Technion - Israel Institute of Technology | Haifa | Israel | Participant |
| The Foundation for Medical Research Infrastructural Development and Health Services Next to the Medical Center Tel Aviv | Tel Aviv | Israel | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Cellularis Biomodels Lda | Ilhavo | Portugal | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI